On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year and beating the consensus estimate of $16.47 billion.

。

Excluding the impact of foreign exchange, sales increased 7%.

不包括外汇的影响，销售额增长了7%。

Merck reported adjusted EPS of $1.57, down from $2.13 a year ago, beating the consensus of $1.51.

默克公布调整后每股收益为1.57美元，低于一年前的2.13美元，超出了普遍预期的1.51美元。

The pharmaceutical unit booked $14.94 billion in revenue, up 5% year over year.

该制药部门实现收入149.4亿美元，同比增长5%。

The increase was driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines, and virology.

这种增长是由肿瘤学和心血管疾病的增长所驱动的，部分被糖尿病，疫苗和病毒学的下降所抵消。

Also Read: CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck’s Pneumococcal Vaccines

另请阅读：疾病预防控制中心和预防咨询小组支持扩大使用辉瑞和默克的肺炎球菌疫苗

Merck’s blockbuster cancer immunotherapy Keytruda generated $7.43 billion in revenue during the quarter, up 17% from the year-earlier period.

默克公司的重磅炸弹癌症免疫疗法Keytruda在本季度产生了74.3亿美元的收入，比上年同期增长了17%。

Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in China, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, and higher demand in most international regions..

默克公司（Merck）报告称，Gardasil的销售额下降了11%，至23.1亿美元，这是一种预防HPV（美国最常见的性传播感染）引起的癌症的疫苗，由于中国的需求减少，部分被美国的销售额增加所抵消，这是由公共部门的购买模式、更高的价格和需求以及大多数国际地区的更高需求驱动的。。

The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $149 million.

新批准的Winrevair（sotatercept）治疗成人肺动脉高压的销售额为1.49亿美元。

Guidance: Merck revised and narrowed its full-year 2024 forecasts.

指引：默克公司修订并缩小了2024年全年预测。

The company expects 2024 sales of $63.6 billion–$64.1 billion, compared to prior guidance of $63.4 billion–$64.4 billion and a consensus of $64.2 billion.

该公司预计2024年销售额将达到636亿美元至641亿美元，而此前的预期销售额为634亿美元至644亿美元，共识销售额为642亿美元。

The U.S. pharma giant expects 2024 adjusted EPS of $7.72–$7.77, compared to prior guidance of $7.94 to $8.04 and consensus of $7.74.

这家美国制药巨头预计2024年调整后每股收益为7.72-7.77美元，而此前的预期为7.94-8.04美元，普遍预期为7.74美元。

Outlook reflects a net negative impact of $0.24/share related to business development transactions with Curon Biopharmaceutical and Daiichi Sankyo.

前景反映出与Curon Biopharmaceutical和Daiichi Sankyo的业务发展交易产生0.24美元/股的净负面影响。

Price Action: MRK stock is down 3.3% at $101.47 at last check Thursday.

价格走势：MRK股价周四最后一次下跌3.3%，至101.47美元。

Read Next:

阅读下一页：

Estée Lauder Q1 Earnings: China Uncertainty Hits Beauty Giant, Withdraws FY25 Outlook, Stock Tanks

雅诗兰黛第一季度收益：中国不确定性打击美容巨头，撤回25财年展望，股票下跌

Image courtesy of Merck.Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

图片由默克公司提供。Benzinga API为您带来的市场新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。